



Our lives, redefined

UBS Healthtech Summit 2023



24 May 2023

Raffles Hotel Jubilee Ballroom

8:00 – 9:00am

Registration and breakfast
Buffet breakfast at foyer

9:00 – 9:10am

Opening address

Edmund KOH
President Asia Pacific, Member of the Group Executive Board, UBS AG

9:10 – 9:40am

Keynote address

Future-care redefined: how advancement in healthcare will change our lives forever

The emergence of advanced and more powerful technologies such as artificial intelligence (AI), virtual and augmented reality has completely transformed the healthcare landscape. ChatGPT, an AI chatbot developed by OpenAI for example, is already working on drug discoveries. Patients could potentially turn to chatbots for valuable and reliable medical information before they visit their physician. The list and possibilities are endless.

Developments at such breakneck speed is unprecedented – how can the healthcare industry narrow the gap? What can we do to fully embrace innovation and revolutionize healthcare delivery?

But more importantly, how can technology improve patient outcomes, reduce costs and empower individuals with the correct tools and information to make their own decisions when it comes to their own health? How can we move from sick care to health care? Why should healthcare providers be more proactive in preventing diseases, rather than just treating them?

Daniel KRAFT
Stanford and Harvard trained MD, Physician-Scientist and Inventor,
Founder, NextMed Health and Digital.Health,
Chair, XPRIZE Pandemic and Health Alliance,
Founder, Exponential Medicine

9:40 – 10:10am

Session 1: Plenary discussion

Preventive care redefined: the approach to never falling sick

With healthcare costs on the rise, preventive care reduces the need for more costly and invasive medical interventions. The traditional healthcare system has often been organized in silos, leading to fragmented care gaps resulting in poor outcomes for patients.

How are some of the medical firms working together to achieve a collaborative ecosystem to help and prevent individuals from ever falling sick?

Moderated by
Dr. ZHOU Lihan
Co-founder & CEO,
MiRXES Group

Panelists
Dr. Jeremy LIM, Co-founder & CEO, AMILI
Levana SANI, Co-founder & CEO, Nalagenetics
Ray ZHANG, Founder, Beijing Airdoc Technology Co Ltd

10:10 – 10:30am

Session 2: Plenary discussion
Healthcare redefined: the evolution of precision medicine and targeted therapy

How does precision medicine differ from traditional cancer therapies? Our panelists will explore the principles behind precision medicine and its personalized approach to treatment, contrasting it with conventional methods, as well as the challenges faced by cancer patients in regions with limited drug availability and high treatment costs.

Have you pondered how artificial intelligence (AI) could transform cancer treatment? What is the potential impact of AI in diagnosis, prognosis, personalized treatment selection, and drug discovery?

What are the current growth trends of cell and gene therapy (CGT) and how has it evolved? We'll also address the challenges faced by early and growth-stage CGT startups offer insightful advice for early-stage players.

Could Singapore be a potential hub for cell and gene therapy medical tourism? What are its strengths in terms of infrastructure, regulations, research capabilities, and healthcare system?

Moderated by
LEE Wen Ching
 CIO Equity Strategist,
 UBS Global Wealth Management

Panelists
SIE Djohan, CEO, Kalbe Genexine Biologics (KGBio),
 Director, PT Kalbe Farma Tbk
Thomas WILLEMSEN, President & CEO, Tessa Therapeutics

10:30 – 11:00am

Networking break

11:00 – 11:30am

Session 3: Plenary discussion
Healthcare redefined: bridging the online-to-offline patient experience

If you are a parent, you will understand the stress and anxiety of dealing with a sick child while waiting hours to see a pediatrician, or needing immediate medical attention in the middle of the night when all the clinics are closed. In such situations, telemedicine can be incredibly helpful for both parent and child through access to medical care at any time of the day or night.

And as demand for such healthcare services increases, mobile applications such as the one developed jointly by Thomson Medical Group and WhiteCoat targeting women and children will come in useful. The app also aims to bridge the online-to-offline patient experience and optimize health and wellness needs.

Where are the opportunities for on and offline businesses to collaborate and create a comprehensive service offering to patients? How can technology carve out new ways to manage our health while harnessing synergy with traditional hospitals?

Moderated by
Michele LIM
 Circle One by UBS, APAC Head,
 UBS Global Wealth Management

Panelists
Dr. Melvin HENG, Executive Director & Group CEO,
 Thomson Medical Group
Bryan KOH, Founder & CEO, WhiteCoat Global Holdings Pte. Ltd.

11:30 – 12:00pm

Session 4: Presentation with fireside chat
Longevity redefined: living better longer

What came first, longevity or optimism? For millennia humanity have searched for the elixir of life, and with advancement in the medical industry, living beyond 100 is no longer insurmountable.

The United Nations has predicted the number of centenarians to grow from half a million in 2021 to a whopping 3.7 million by 2050. But what about the science on living better? How can we achieve an optimal outcome between genetics and lifestyle when it comes to aging?

Speaker / Moderator
Jim MELLON
 Co-founder & Deputy Chairman,
 Juvenescence

Fireside chat with
Michael HUFFORD, Ph.D.
 Co-founder & CEO, LyGenesis

12:00pm

Sit-down lunch served: appetizer and main course

12:00 – 1:00pm

Discovery showcases

Speakers from across the globe will showcase some of the most revolutionary medical technologies in the healthcare industry in a TED-talk style presentation.

Speakers

1. **Dr. Hoai Nghia NGUYEN**, Co-founder, CEO and Head of R&D, Gene Solutions
2. **Aniket Singh RAJPUT**, Founder & CEO, Neuroglee Therapeutics
3. **Dr. Rajarshi BANERJEE**, CEO, Perspectum
4. **Rene RAISS**, Co-founder & A.I. Architect, SQREEM Technologies
5. **Ian LEE**, Deputy CFO, XtalPi

1:00 – 1:30pm

Session 5: Plenary discussion**Impact redefined: coming together for a better world**

What should companies do to capture the attention of larger investments?

Factors such as support in development of medical treatments, improved healthcare access and job creation leads to better patient outcomes and economic growth - a boon for all.

How do we measure impact of healthcare on our society, both in short and long term, and what can the industry do to ensure better healthcare access for all?

Moderated by
Edward BOOTY
CEO, reach52

Panelists
Scarlett CHEN, Managing Partner, Verge Healthtech Fund
Prof. TAN Sze Wee, Assistant Chief Executive Innovation & Enterprise, A*STAR
Matteo THUN, Partner, EQT group

1:30 – 1:35pm

Closing address

Patricia QUEK
IBF Fellow, Business Sector Head, Singapore and Malaysia, UBS Global Wealth Management

1:35pm onwards

Networking and dessert



Discovery booths

Full day

Learn more about the many facets of healthtech through our discovery booths – from precision surgery to longevity diagnostics and gut health. Our discovery booths are located at the Jubilee Foyer outside the ballroom.



Airdoc

Founded in September 2015, Airdoc is an AI-based medical device company with an advanced platform of AI empowered retina-based deep learning algorithms, and professional medical equipment design, R&D, registration and production teams, devotes to providing comprehensive and multi-faceted AI-based solutions for early screening and management on chronic diseases, and myopia prevention and control, which is a global market leader and pioneer in the field of AI-based retinal imaging. On November 5, 2021, Airdoc was successfully listed on the Stock Exchange (stock code: 2251) and became the first HK-listed medical AI company.



AMILI

BIO & ME is part of AMILI, Southeast Asia's first and only precision gut health company. Through BIO & ME, we provide access to important gut microbiome science and innovation.

We believe that 'Good Health Starts with Gut Health' and have designed our gut health solutions to provide extensive and actionable insights to improve our customers' gut microbiome. Our at-home gut health test (Singapore's first) allows people to discover ways to improve brain health, boost immunity, or enhance metabolism. We also offer targeted probiotic formulations tailor-made for people living in Asia.

We're passionate about advancing human health and to positively impact the lives of millions of people through microbiome science.



Chi Longevity

Chi Longevity is an expert-led centre of excellence providing a scientific-based proactive approach to ageing to guide individuals towards a younger, healthier self. A global leader in researching gerontology and internal medicine, Professor Andrea Maier (world renowned leader in Longevity Medicine) leads the medical suites' programs and is supported by a team of healthcare specialists who curate a wholly personalised journey to promote vitality and prolong longevity. Health spans are optimised using cutting-edge diagnostics and multi-disciplinary interventions that target the ageing process.

The Chi Longevity journey begins with a multi-dimensional biological, clinical and digital diagnostic assessment to build an individual's unique health profile and highlight the precise hallmarks of biological ageing. A comprehensive evaluation of habits and preferences such as sleep, diet, stress levels, and exercise regimen is also conducted to supplement the analysis. Once the results are revealed, a personalised intervention plan to curate a longevity strategy is implemented, featuring evidence-based therapeutics, supplements and changes to lifestyle, social and physical environments.

The medical suites' expert team of physicians, dieticians, psychologists and health coaches review and support the age-reversal program at every step of the way. Remote monitoring technologies are linked to an advanced digital health dashboard to enable up-to-the-minute recording of progress. Once the initial regimen is completed, progress is evaluated to observe changes in biomarkers, biological clocks, and the overall ageing process. After thorough analysis, Chi Longevity's specialists devise a follow-up plan to sustain gains and promote further health goals.



Nalagenetics

Nalagenetics is a biotechnology company developing genetic interpretation kit and software. Nalagenetics aims to partner with labs to provide an affordable and actionable end-to-end genetic testing that is relevant to the local populations. The first use case is pharmacogenomics, genetic testing for personalized prescriptions in chronic conditions. The second is risk prediction using whole genome sequencing for chronic and neurodegenerative conditions. It has market presence in Southeast Asia and Europe.

Currently, Nalagenetics has received US\$12.6m from Series A funding from global investors and was selected as the 1st place winner in the Mobility and Healthcare categories at the 2021 G20 Innovation League event.



NDR Medical Technology


NDR Medical Technology was founded in 2015 and developed the patented Automated Needle Targeting system (ANT) that can facilitate safe and accurate needle punctures to organs such as the lungs, kidney, pancreas, and spine. Integrating AI and robotics, we empower surgeons to conduct pioneer image-guided robotic procedures with improved accuracy, precision, and safety for patients.

Our first interventional robot (ANT-X) integrates C-arm fluoroscopy and AI software to assist clinicians in percutaneous needle placements and can be used in a wide range of procedures such as urology, neurology, and orthopedics. ANT-C is a smart lesion targeting system that AI uses CT-scan images to automate lesion detection, needle path planning and needle targeting with unparalleled precision and accuracy. Applications include usages in pulmonology and hepatology. As a cut above the rest, our robots cost less than half of the current technology out in the market and can function without the need for external sensors.

With a renewed vision to lead AI-empowered interventional robotics, we strive to create revolutionary breakthroughs in the industry and transform the healthcare landscape.



Speakers and topics



Opening address

9:00 – 9:10am

Edmund KOH

President Asia Pacific,
Member of the Group Executive Board,
UBS AG

Edmund Koh, a Singaporean, joined UBS in February 2012 as Group Managing Director, heading the UBS Wealth Management South East Asia and Asia Pacific Hub. He became a member of the Group Executive Board and was appointed President UBS Asia Pacific of UBS Group AG and UBS AG in January 2019. He was also Head Wealth Management Asia Pacific from 2016 – 2018 as well as Country Head Singapore from 2012 – February 2019.

Edmund oversees all the businesses across 13 locations in Asia Pacific and meets with key regulators and government officials regularly to exchange views on market and geopolitical development, and financial markets opening and policies. He has been invited to speak in various forums including the Institute of International Finance membership meeting.

Edmund is a strong advocate of talent management and community involvement. He launched the UBS Youth Finance Academy in 2014 to build the talent pipeline for Singapore's financial industry and led and advocated for the implementation of 17 projects across Asia Pacific under the UBS COVID-19 Relief Funds program which totaled USD 30 million globally in 2020.

With more than 30 years' experience in senior roles in financial services, Edmund is a board/council member of various committees including the MAS Financial Centre Advisory Panel, the Wealth Management Institute, the Asian Bureau of Finance and Economic Research, and the University of Toronto International Leadership Council. He was also named a Distinguished Fellow by The Institute of Banking & Finance Singapore in 2017.

Edmund had also served as a Board member at the Singapore Housing Development Board for a period of 12 years from 1998 to 2010, Vice-Chairman of the Singapore Sports Council from 2002 to 2010 and Director of Singapore Totalizator Board from 1998 to 2004.

Edmund holds a Bachelor of Science in Psychology from the University of Toronto, Canada.



Speakers and topics



Keynote address

Future-care redefined: how advancement in healthcare will change our lives forever

9:10 – 9:40am

Daniel KRAFT

Stanford & Harvard trained MD, Physician-Scientist & Inventor,
 Founder, NextMed Health & Digital.Health,
 Chair, XPRIZE Pandemic & Health Alliance,
 Founder, Exponential Medicine

Daniel Kraft is a Stanford and Harvard-trained physician-scientist, inventor, entrepreneur, and innovator. He is co-founder and partner at Continuum Health Ventures (focused on seed-stage Digital Health and Longevity) and is serving as the Chair of the XPRIZE Pandemic & Health Alliance Task Force. With over 25 years of experience in clinical practice, biomedical research and healthcare innovation, Kraft has served as faculty chair for Medicine at Singularity University since its inception in 2008, and is founder and chair of Exponential Medicine, a program that explores convergent, rapidly developing technologies and their potential in biomedicine and healthcare. Following undergraduate degrees from Brown University and medical school at Stanford, Daniel was Board Certified in both Internal Medicine & Pediatrics after completing a Harvard residency at the Massachusetts General Hospital & Boston Children's Hospital, and fellowships in hematology, oncology, and bone marrow transplantation at Stanford where he completed a post-doc in the laboratory of Irving L Weissman, with publications including in Science and Nature.

Daniel is a member of the Inaugural class of the Aspen Institute Health Innovators Fellowship and is member of the Kaufman Fellows Society.

He is often called upon to speak to the future of health, medicine and technology and has given four TED and two TEDMED Talks and has delivered keynotes to a diverse array of organizations.

He has multiple scientific publications (including in Nature and Science) and medical device, immunology, and stem cell-related patents through NIH-funded faculty positions with Stanford University School of Medicine and as clinical faculty for the pediatric bone marrow transplantation service at the University of California San Francisco.

Daniel's academic research has focused on: stem cell biology and regenerative medicine, stem cell-derived immunotherapies for cancer, bioengineering human T-cell differentiation, and humanized animal models. His research has been published in journals that include Nature and Science. His clinical work has focused on: bone marrow / hematopoietic stem cell transplantation for malignant and non-malignant diseases in adults and children, medical devices to enable stem cell based regenerative medicine, including marrow derived stem cell harvesting, processing and delivery.

He is heavily involved in digital health, founded Digital.Health, and is on the board of Healthy.io and advises several Fortune-50 and digital health-related startups. Daniel recently founded IntelliMedicine, focused on personalized, data-driven, precision medicine. He is also the inventor of the MarrowMiner, an FDA-approved device for the minimally invasive harvest of bone marrow, and founded RegenMed Systems, a company developing technologies to enable adult stem cell-based regenerative therapies.

Daniel is an avid pilot and has served in the Massachusetts and California Air National Guard as an officer and flight surgeon with F-15 & F-16 fighter Squadrons. He has conducted research on aerospace medicine that was published with NASA, with whom he was a finalist for astronaut selection.

AWARDS

- The Most Influential Voices in Healthcare for 2022 (Medika Life)
- 40 of the Smartest People in Healthcare
- The Top-10 Internet Smart Doctors in the World (2013)
- Pharma Voice 100: Annual list recognizes the most inspiring leaders in Life Sciences, as determined by their readers.
- Digital Health Top-50 (2016)
- NIH K-08 Physician-Scientist Award
- NIH SBIR Phase I / Phase II Award
- HHMI Continuing Studies Scholarship



Speakers and topics



Session 1:
Preventive care redefined: the approach to never falling sick

9:40 – 10:10am

Dr. Jeremy LIM
Co-founder & CEO, AMILI

Assoc Prof Jeremy Lim is Co-Founder and CEO of AMILI, the region's first precision microbiome company. He brings diverse and unique perspectives into the startup space, having spent substantial time in public and private healthcare across Asia as well as in policy advisory with Singapore's Ministry of Health, the World Bank and the World Health Organization. His last role in SingHealth, Singapore's largest healthcare group, was in leading the research and educational organizations. Jeremy is also director of global health in the National University of Singapore Saw Swee Hock School of Public Health.

Outside AMILI & academia, Jeremy serves on the boards of various for-profit and not-for-profit organizations in different aspects of healthcare including digital health interventions and service provision. He trained in surgery and public health, attaining post-graduate qualifications in both from the UK and US.



Session 1:
Preventive care redefined: the approach to never falling sick

9:40 – 10:10am

Levana SANI
Co-founder & CEO, Nalagenetics

Levana Sani is the co-founder and CEO of Nalagenetics, a biotechnology startup that focuses on personalized healthcare through genetic testing to provide the best treatment solutions that are more affordable and safer for patients.

Levana studied biochemistry, genetics, and business and holds a Bachelor of Biochemistry from the University of Southern California followed by an MBA from Harvard Business School. While being a part of the Genome Institute of Singapore, Levana and a team of scientists founded Nalagenetics in 2016. Her contributions to Nalagenetics led to Levana being selected in the "Forbes 30 under 30" in 2021.

Nalagenetics has received US\$12.6m from Series A funding and was selected as the 1st place winner in the Mobility and Healthcare categories at the 2021 G20 Innovation League. On the following year, Nalagenetics became part of Singapore's SG100K, a study to map the genome of 10,000 participants to develop better tools through precision medicine to predict and prevent chronic diseases among Singaporeans and other Asians populations.

Today, Nalagenetics' solutions are offered by a growing number of healthcare providers and laboratories in Asia and Europe, reflecting the company's exceptional standards and depth of research as a scientist-led company.



Session 1:
Preventive care redefined: the approach to never falling sick

9:40 – 10:10am

Ray ZHANG
Founder, Beijing Airdoc Technology Co Ltd

Ray Zhang is the founder of Beijing Airdoc Technology Development Co., Ltd. (Airdoc) and serves as the secretary-general of the Smart Medical Committee of the Chinese Association for Artificial Intelligence, the vice chairman of the Industry Development and Coordination Committee of the Asian Optometry Practice Management Association, and the chairman of the China Optometry Industry Vice Chairman of the Alliance and Standing Committee Member of Mobile Health Branch of China Health Promotion and Education Association. Prior to his current roles, he was the former Excel Product Manager at Microsoft Headquarters, vice president of PPTV, and the vice president of Sina.



Speakers and topics



Session 1:
Preventive care redefined: the approach to never falling sick

9:40 – 10:10am

Dr. ZHOU Lihan
Co-founder & CEO, MiRXES Group

Lihan co-founded and serves as CEO of MiRXES, a Singapore headquartered, RNA centric biotechnology company with the mission to improve and save lives through early, actionable and personalized diagnosis. Lihan oversees MiRXES group's overall strategy and global operations in Singapore, USA, China and Japan with a team of 360 staff.

Prior to founding MiRXES in 2014, Lihan was a research scientist at the Bioprocessing Technology Institute, A*STAR where he co-developed a novel microRNA qPCR assay platform for microRNA biomarker and therapeutic target discovery. As a scientist-entrepreneur, Lihan is driving ground-breaking RNA research and actively champions a global ecosystem and standards to accelerate clinical adoption of RNA diagnostics.

Under Lihan's leadership, MiRXES was named Singapore's Most Promising Start-up in 2016 and Singapore's Fastest Growing Companies in 2018, 2019 and 2020. MiRXES has successfully raised USD \$130 million venture funding since 2016, which is among the highest raised by an Asia based genomics companies.

Lihan was recognized by the MIT Technology Review as a member of the Innovators Under 35 (2015). He was also awarded the A*STAR Scientist-Entrepreneur Award together with his co-founders in 2017, the NUS Outstanding Young Alumni Award and the EY Entrepreneur of The Year™ Singapore awards (Overall Winner & Biotechnology category) in 2021. Lihan has been serving on the Board of Enterprise Singapore since April 2022. Lihan obtained his Ph.D. in Biochemistry from Yong Loo Lin School of Medicine, National University of Singapore. He has authored and co-authored more than 25 peer-reviewed publications and several patent applications.



Session 2:
Healthcare redefined: the evolution of precise medicine and targeted therapy

10:10 – 10:30am

SIE Djohan
CEO, Kalbe Genexine Biologics (KGbio), Director, PT Kalbe Farma Tbk

Director of the Company since 2017. First appointed as Director of the Company based on the resolution of the Annual General Meeting of Shareholders dated June 5, 2017 and was then reappointed as Director based on the resolution of the Annual General Meeting of Shareholders on May 18, 2020.

He started his career at Kalbe Group by serving as Group Marketing Manager at PT Dankos Farma in 1996 until 2001 and in 2001 until 2006 he served as Assistant Marketing Director of PT Dankos Farma. In 2006 until 2007 he served as Assistant Director of Corporate Business Development & Management System of PT Kalbe Farma Tbk and in 2007 until present as Director of Corporate Strategic Investments, Corporate Business Development, and Corporate Regulatory Affairs and QA of PT Kalbe Farma Tbk.

Currently he also serves as President Commissioner of PT Innolab Sains Internasional, President Director of PT Bifarma Adiluhung, President Director of PT Kalgen DNA, President Director of PT Kalbe Genexine Biologics, President Director of PT Kalbe Biotek Indonesia, President Director of PT Kalbio Global Medika, and Director of Innogene Kalbiotech Pte. Ltd.

He received his Bachelor degree in Pharmacy from the University of Indonesia in 1990.

He does not have any affiliation with the Company's members of the Board of Commissioners, the Board of Directors, nor with the Company's majority shareholder.



Speakers and topics



Session 2:

Healthcare redefined: the evolution of precise medicine and targeted therapy

10:10 – 10:30am

Thomas WILLEMSSEN

President & CEO, Tessa Therapeutics

Thomas Willemsen brings over 25 years of extensive international management and leadership experience in the pharmaceutical industry. He joined Tessa from Takeda Pharmaceuticals, where he served as Senior Vice President, Asia Pacific, leading the transformation of Takeda across 10 markets enhancing the focus on rare and genetic diseases, oncology, and vaccines, based in Singapore.

Prior to Takeda, Thomas held the position of Vice President, Oncology at GlaxoSmithKline (GSK) for its Intercontinental & Emerging Markets business, where he was assigned to develop the business' strategy for Asia & Emerging Markets, including Access Strategy and Commercial structure design.

Prior to that, Thomas served as Chairman and General Manager for GSK in China, and as General Manager of GSK Taiwan. He also spent 12 years with Merck KGaA in various commercial and regional roles in the Asia Pacific region, and as the Head of its German Oncology business unit.

Thomas speaks German, English and Mandarin. He graduated with an MBA from Trier University, Germany, and attained a Chinese Language Degree from Sun Yat-Sen University, Guangzhou, China.



Session 2:

Healthcare redefined: the evolution of precise medicine and targeted therapy

10:10 – 10:30am

LEE Wen Ching

CIO Equity Strategist, UBS Global Wealth Management

Lee Wen Ching joined UBS Singapore as a Singapore equity analyst in July 2013, focusing primarily on Singapore-listed equities. She was previously a sell-side equity analyst with CIMB and OCBC. Wen Ching has won several personal accolades such as the StarMine best stock picker and best earnings estimator awards. Prior to her career in equities research, Wen Ching worked with the Singapore Exchange.

Wen Ching is responsible for running the Singapore equity preference list as well as providing bottom-up research to the strategy team and providing thematic ideas.

Wen Ching is often interviewed by Channel News Asia, and quoted on Reuters, Dow Jones, Bloomberg, Business Times Singapore, Straits Times, The Edge and various media publications in Singapore.

Wen Ching holds a bachelor's honours degree in Banking & Finance from the Nanyang Technological University in Singapore.



Speakers and topics



Session 3:
Healthcare redefined: bridging the online-to-offline patient experience

11:00 – 11:30am

Dr. Melvin HENG
Executive Director & CEO, Thomson Medical Group

Dr. Melvin Heng was appointed as Executive Director and Group Chief Executive Officer on 1 December 2022. He leads and manages the Group and works actively with the Board and Management to set the overall strategic direction focused on driving business operations and growth of the Group.

Dr. Heng is a physician and healthcare executive with more than 10 years of experience in hospital management, primary and specialist clinics, teleradiology, MedTech and aeromedical evacuations. Dr Heng is a medical advisor and investor in several MedTech companies such as Mesh Bio and Global Health Byte (now UNO Technologies). From 2016 to 2018, Dr Heng served as an advisor to the Ministry of Health in the Primary Care IT sub-committee for National Electronic Health Records and GP Connect. Before joining Thomson Medical, Dr Heng was with Gleneagles Hospital where he held various leadership positions including Chief Executive Officer and Chief Operating Officer. From 2009 to 2015, Dr Heng was a medical doctor with the National Health Service (United Kingdom) and Tan Tock Seng Hospital. After leaving the public service, Dr Heng co-founded an aeromedical evacuation company (Global Medical Concierge) and was also an equity partner at OneCare Medical, a chain of primary care clinics.

Dr. Heng was awarded the Public Service Medal (COVID-19) by the Singapore Government in 2023.



Session 3:
Healthcare redefined: bridging the online-to-offline patient experience

11:00 – 11:30am

Bryan KOH
Founder & CEO, WhiteCoat Global Holdings Pte. Ltd.

Bryan is the founder of WhiteCoat, a digital healthcare company that is transforming the healthcare landscape in Asia. WhiteCoat's mission is to become the first and single touchpoint for all health needs across the region.

With a focus on providing accessible and affordable high-quality care through a B2B2C approach, WhiteCoat has formed strategic partnerships with the region's leading insurers, corporates and healthcare providers to provide a wide range of tele- and in-person healthcare services across primary, specialist and allied care, as well as medication fulfillment and diagnostic testing, to a growing base of over 1.5 million lives in the region.

Prior to founding WhiteCoat, Bryan was a Corporate Mergers & Acquisitions lawyer with Allen & Gledhill LLP, a leading law firm in Singapore. He is qualified to the Singapore bar and holds a Bachelor of Laws and a Bachelor of Commerce from the University of Melbourne.



Session 3:
Healthcare redefined: bridging the online-to-offline patient experience

11:00 – 11:30am

Michele LIM
Circle One by UBS, APAC Head, UBS Global Wealth Management

Michele Lim is Head of Circle One by UBS APAC, a wealth management app for UBS clients delivering world class insights at their fingertips. Circle One first launched in APAC in 2022 and has since grown into an omnichannel experience. In the next phase, the app will launch Circles, exclusive communities for like-minded peers to network and collaborate.

Michele spent her first 20 years as an investment banker at J.P. Morgan in various leadership positions, including Head of IB Equities for South-East Asia. A strong advocate for diversity, she chaired J.P. Morgan's inaugural Women's Leadership Network in Singapore.

She is a fan of Peter Thiel's book on Entrepreneurship, Zero to One, and enjoys learning through podcasts and audiobooks. She is passionate about growth strategies and inspired by visionary leadership.

For more on Circle One by UBS: ubs.com/circleone



Speakers and topics



Session 4:
Longevity redefined: living better longer

11:30am – 12:00pm

Jim MELLON

Co-founder & Deputy Chairman, Juvenescence

Jim Mellon is a British entrepreneur, investor and philanthropist with a wide range of interests. Through his private investment company, Burnbrae Group, he has substantial real estate holdings in Germany and the Isle of Man, as well as holdings in private and public companies.

Jim holds a master's degree in Politics, Philosophy and Economics from the University of Oxford and, since graduating in 1978, his entire career has been spent in asset management. He spent his early career specialising in emerging markets before becoming a major investor in a broad range of sectors including property, natural resources and biotechnology. Jim is a director and major shareholder of several companies including - Chairman of Manx Financial Group, controlling shareholder and Chairman of Endurance RP Group, a Hong Kong-based investment company which focuses on the healthcare and late-stage life sciences sectors, and co-founded Juvenescence, a company developing therapies for longevity and Agronomics to invest in a portfolio of leading companies in the field of cellular agriculture.

A noted author, Mr Mellon has written several books, most recently Moo's Law, focusing on investment opportunities in the field of cellular agriculture - the production of proteins and materials directly from cells. His other titles include Juvenescence: Investing in the Age of Longevity and Wake Up! Survive and Prosper in the Coming Economic Turmoil, which predicted the economic downturn of 2007 and 2008.

Jim sits on the Board of Trustees of the Buck Institute for Research on Aging, and of the American Federation for Aging Research (AFAR). He is an Honorary Fellow of Oriel College at the University of Oxford, where he has established the Mellon Centre for Longevity, and he also sits on the Advisory Board of the Milken Institute's Centre for the Future of Aging.



Session 4:
Longevity redefined: living better longer

11:30am – 12:00pm

Michael HUFFORD, Ph.D.

Co-founder & CEO, LyGenesis

Michael Hufford, Ph.D. is the Co-Founder and CEO of LyGenesis, a clinical-stage drug development company whose cell therapies use lymph nodes as bioreactors to grow functioning ectopic organs. He is also the Interim CEO of MorphoCeuticals, a startup pioneering the bioelectric reprogramming of biology. An entrepreneur and drug developer, he has over 20 years of experience in the development and regulatory approval of small molecules, biologics, as well as drug delivery technologies. He has designed and executed clinical trials across a wide variety of therapeutic areas, from orphan metabolic diseases to psychiatry and oncology. His philanthropic work includes co-founding Harm Reduction Therapeutics, a nonprofit pharmaceutical company developing low- cost over-the-counter naloxone in the US to help prevent opioid overdose deaths.

Dr. Hufford earned his undergraduate degree with distinction from Purdue University, and his master's and doctoral degrees in clinical psychology from the University of Pittsburgh before completing a Research and Clinical Fellowship in the Department of Psychiatry at Harvard Medical School. He is the author of more than 100 scientific publications, presentations, and OpEds, with multiple issued and pending patents.



Speakers and topics



Discovery showcases

12:00 – 1:00pm

Dr. Hoai Nghia NGUYEN

Co-founder, CEO, and Head of R&D, Gene Solutions

Dr. Nghia co-founded Gene Solutions in 2017 and transformed it into a leading genetic testing company in Vietnam. At Gene Solutions, he is responsible for not only strategic development but also R&D outcomes. He is also a principle investigator at the Medical Genetics Institute and the University of Medicine and Pharmacy in Ho Chi Minh City.

Prior to his current positions, Dr. Nghia obtained his PhD from Oklahoma State University before completing postdoctoral fellowships at Johns Hopkins University School of Medicine and U.S. National Institutes of Health (NIEHS). His research focuses on the molecular basis of cancer transformation, migration and metastasis, as well as the development of liquid biopsy-based clinical applications in early cancer detection, minimal residual disease detection, and therapy selection. He has co-authored more than 36 international peer-reviewed publications related to his areas of expertise, including articles in the Developmental Biology, Cell Signal, Oncogene, Proceedings of the National Academy of Sciences, and Scientific Reports. His research has uncovered new insights into the genetic and molecular mechanisms underlying cancer progression and metastasis and has the potential to lead to improved methods for cancer diagnosis and treatment.



Discovery showcases

12:00 – 1:00pm

Aniket Singh RAJPUT

Founder & CEO, Neuroglee Therapeutics

Aniket Singh Rajput is the CEO and Founder of Neuroglee, a fast-growing digital health company filled with committed, passionate people who are driven to the mission of Reimagining Cognitive Care to empower people living with neurological conditions and their families to lead productive, meaningful lives by revolutionizing personalized healthcare and the patient experience.

Neuroglee is breaking new ground by offering first-of-their-kind virtual specialty care clinics for patients diagnosed with mild cognitive impairment related to difficult-to-treat conditions such as Alzheimer's disease and Dementia. Neuroglee combines digital solutions with expert clinical support to deliver personalized, evidence-based cognitive care at the comfort of patient's home.

Recognized as the "Forbes 30 Under 30", Aniket has demonstrated strong leadership experience by building amazing teams, developing talents, and successfully growing, and managing strategic partnerships with global Hospital Systems and Pharma. Under his leadership, Neuroglee has raised over US\$12 Million in Venture Capital from leading Venture Capital firms and Pharma including, Eisai Pharmaceuticals, Singapore Govt-linked EDBI and OpenSpace Ventures.

He uses his background in Cognitive Neuroscience and Robotics to unfold his vision of "Reimagining Care for Patients suffering from Neurological conditions". During his Ph.D. studies at Nanyang Technological University (NTU), his work focused on designing platform and algorithms for therapy and rehabilitation to treat and manage patients with Stroke and Parkinson's disease.

He believes in giving back, supporting the mission of providing people access to education and healthcare for stable economic growth. Aniket has also been featured in major articles including WSJ.

Specialties: Entrepreneur, Fund Raising, Licensing and Deal Structure, Healthcare Strategy, Digital Healthcare, Digital Therapeutics, Virtual Care, Cognitive Neuroscience, Cognitive Behaviour Therapy, Human Computer interaction, Machine learning, Wearable Biosensors, Pharmaceuticals.



Speakers and topics



Discovery showcases

12:00 – 1:00pm

Dr. Rajarshi BANERJEE

CEO, Perspectum

Rajarshi Banerjee, Ph.D. is Chief Executive Officer of Perspectum. Prior to co-founding Perspectum in 2012, Dr. Banerjee was a research fellow at the University of Oxford and developed the magnetic resonance imaging techniques for rapid non-invasive liver assessment and commercialized the method as LiverMultiScan, which has received 510(k) clearance from the FDA and is used in over 250 sites. Dr. Banerjee continues to work as a consultant physician with the Oxford University Hospitals NHS Foundation Trust, with research into the phenotyping of liver disease at an individual and population level in adults and children.

Dr. Banerjee has many years of experience in running clinical trials and working in multidisciplinary scientific teams to develop applications for cutting-edge imaging technology and is a keen advocate of smart trial design. Dr. Banerjee received a BM. BCh. in Medicine and a Ph.D. in Cardiovascular Health from the University of Oxford, as well as a MSc. in Public Health from the London School of Hygiene and Tropical Medicine.

Website: <https://www.perspectum.com/our-company/>



Discovery showcases

12:00 – 1:00pm

Rene RAISS

Co-founder & A.I. Architect, SQREEM Technologies

Rene Raiss is a Co-Founder and A.I. Architect at SQREEM Technologies, who graduated from Columbia University. He has more than 20 years of experience in quantitative and complex systems engineering, and over 10 years of experience in Asset Management. He is also the Founder of PRECISE Capital and has managed three hedge funds, focusing on long/short equity and derivatives trading.

Rene Raiss began his career with Merrill Lynch Scientific Group in the US, where he developed the first generation neural-network trading and analysis algorithms. He is currently responsible for the origination and design of all SQREEM AI platforms, algorithms, and capabilities, as well as managing all data acquisition and back-end architecture development.



Discovery showcases

12:00 – 1:00pm

Ian LEE

Deputy CFO, XtalPi

Ian Lee is currently deputy CFO at XtalPi Inc. where he leads the company's strategic growth through acquisition, as well as the company's incubation efforts.

He remains operationally involved and sits on the boards of active portfolio companies.

Prior to XtalPi, Ian started his career in venture capital. He was first introduced to the VC industry while serving as an analyst at DN Capital, London. He authored a report on the applications of mobile apps at the cusp of the introduction of smartphones as a platform. His conclusion on the utilitarian aspect of phone apps led to the firm's participation in deals such as Shazam (acquired by Apple), Digital Chocolate, Achica, and more.

After spending three years at DN Capital, he joined Turing Award winner – Michael Stonebraker's and serial entrepreneur Andy Palmer's tech focused fund and incubator – Koa Labs. While at Koa Labs, Ian managed the portfolio of 30+ startups from Recorded Future (acquired by Insight Partners) and Desktop Metal, to Upstart and Carta (formerly eShares) and many more.

Ian then raised and executed his first fund, co-founding Leather District Ventures [LDV], in Cambridge, MA. While managing LDV, Ian also served as a board member to Conjur (acquired by Cyberark).

Ian holds a Bachelor of Arts from Bowdoin College in Maine, graduating with an independent study in The Private Equity and Venture Capital industry.

While at Bowdoin, he co-founded Bowdoin's first entrepreneurship group. Additionally, he was on the rugby team and the varsity sailing team.

Ian is based in Boston, MA where he serves as a guest lecturer and panelist at MIT and MIT CHIEF.



Speakers and topics



Session 5:
Impact redefined: coming together for a better world

1:00 – 1:30pm

Scarlett CHEN
Managing Partner, Verge Healthtech Fund

Ms. Scarlett Chen is Managing Partner at Verge HealthTech Fund, a VC fund manager focused exclusively on impactful HealthTech startups at a global scale and at the early stage.

Previously as Managing Director at Prudential Corporation Asia, Ms. Chen was responsible for Strategic Investments. Before Prudential, Ms. Chen worked at Anbang Capital as Global Head of Financial Institutions Group where she led a number of outbound investments in Europe and Asia.

Before joining the buy-side, Ms. Chen was an investment banker for over a decade, having worked at Merrill Lynch in the US and Barclays in Hong Kong, where she executed more than US\$30 billion in capital markets and advisory transactions.



Session 5:
Impact redefined: coming together for a better world

1:00 – 1:30pm

Prof. TAN Sze Wee
Assistant Chief Executive Innovation & Enterprise, A*STAR


Prof. Tan is currently the Assistant Chief Executive of A*STAR's Innovation and Enterprise (I&E) Group, comprising the Industry Development Group and A*ccelerate Technologies Pte Ltd. As Assistant Chief Executive (I&E), Prof Tan leads the I&E Group in steering efforts to translate A*STAR's R&D to market so as to enable research-fuelled economic and social impact.

Prof. Tan has been in various leadership roles in A*STAR from 2009 to date, supporting and leading both the Biomedical Research Council (BMRC) and Science and Engineering Research Council (SERC).

Prof. Tan is an Adjunct Professor at Nanyang Technological University's Lee Kong Chian School of Medicine, as well as an Adjunct Professor at Duke-NUS Graduate Medical School Singapore.

Prof. Tan is a member of the Singapore National Eye Centre's Ophthalmic Incubator Board. He is a council member of the Singapore Medical Association, as well as SMA Charity Pte Ltd. He was a former Nominated Member of Parliament of Singapore, and a recipient of Friend of Labour Award and the Public Administration Medal (Silver).

Prof. Tan graduated with MBBS from NUS, and attained his MBA from Warwick University, UK. He attended the Stanford Executive Programme at the Stanford Graduate School of Business. He was awarded a certificate of completion for the Senior Fellowship in Public Service Programme, Lee Kuan Yew School of Public Policy. He is an affiliate member of the Faculty of Pharmaceutical Medicine, Royal College of Physicians, UK.



Session 5:
Impact redefined: coming together for a better world

1:00 – 1:30pm

Matteo THUN
Partner, EQT group

Matteo Thun joined EQT Partners in 2011.

Prior to joining EQT Partners, Matteo worked at J.P. Morgan in London where he was part of the Diversified Industries & Transportation Advisory Group.

Matteo holds an M.A. in Banking and Finance from the University of St. Gallen and an M.Sc. in Management from HEC Paris.



Speakers and topics



Session 5:
Impact redefined: coming together for a better world

1:00 – 1:30pm

Edward BOOTY
CEO, reach52

Edward Booty is the founder and Chief Executive Officer of reach52; a tech startup on a mission to connect the 52% of the world that lacks access to essential health services. The reach52 model trains health workers to collect data, run targeted health awareness, education and screening campaigns, and provide access to essential health products.

Edward has launched reach52 operations in six countries and 2,500 communities – building relationships with over 30 funding partners, and developing the operations and digital platforms to enable this. He has worked in health systems across three continents and 12 countries; and has extensive experience in digital health, health equity, access to medicine and essential health products, public health campaigns, supply chain, government relations and public affairs, private sector engagement strategy and startup operations.

Prior to reach52, he worked in healthcare consulting, for the UK National Health Service (NHS) and for a multinational pharmaceutical company in India, looking at access to medicine in more rural areas. He is a graduate from the London School of Economics (LSE).



Closing address

1:30 – 1:35pm

Patricia QUEK
IBF Fellow, Business Sector Head, Singapore and Malaysia, UBS Global Wealth Management

Patricia Quek heads up UBS WM Singapore & Malaysia business. She is a member of the senior management committee that oversees business strategy, risk management and governance for UBS Singapore. She is responsible for the strategy and alignment of policies for Singapore and Malaysia globally.

Patricia is a client focused, solutions oriented banker with over 25 years of experience, having depth and breadth of experience working with complex multi-shored families, UHNW clients, global family offices, private and public listed companies on diverse financial and family transition topics. She advises UBS key clients and business owners across SEA, drawing on her deep experience and knowledge across Wealth Management, Investment Bank and Asset Management.

Externally, Patricia is a member of the WMI Global-Asia Family Office Partners Committee, supporting efforts in competency and community building. She sits as a committee member of Community Chest, member of the Singapore Institute of Directors & Financial Women Association.